Supreme Court rules 7-2 against Roundup lawsuits
The Supreme Court ruled 7-2 that federal pesticide law preempts state claims, blocking lawsuits against Monsanto over Roundup’s cancer risk. This shields Bayer from thousands of lawsuits but limits co
The U.S. Supreme Court just sided with Bayer’s Monsanto, shielding the company from liability over its Roundup weed killer in a 7-2 decision that stop
Read Full Story at NPR Politics →Why This Matters
The Supreme Court’s decision cements a critical legal precedent that prioritizes federal regulatory uniformity over state-level tort claims, particularly in cases involving federally approved chemicals. For corporations like Bayer, this ruling provides a powerful shield against litigation, while for plaintiffs and public health advocates, it underscores the narrowing pathways to hold industry accountable for alleged harms.
Background Context
Monsanto’s Roundup, introduced in the 1970s, became the world’s most widely used herbicide, with its active ingredient glyphosate long deemed safe by the EPA. However, the International Agency for Research on Cancer classified it as a probable carcinogen in 2015, sparking a wave of litigation that has since burdened Bayer with billions in legal costs and settlements. The company’s 2018 acquisition of Monsanto has kept this financial and reputational crisis at the forefront of corporate legal strategy.
What Happens Next
Bayer will likely move to dismiss the remaining Roundup lawsuits still pending in state courts, leveraging the Supreme Court’s ruling to argue for federal preemption. Meanwhile, plaintiffs’ attorneys may pivot to other legal avenues, such as state-level failure-to-warn claims or claims against other defendants in the supply chain. The decision also invites Congress to clarify the scope of federal preemption in pesticide litigation, a debate that could reshape future regulatory battles.
Bigger Picture
This ruling reflects a broader judicial trend favoring federal regulatory authority in cases where state laws or jury decisions could disrupt national uniformity—seen recently in cases involving pharmaceuticals, medical devices, and environmental regulations. It also highlights the growing tension between corporate accountability and public health litigation, where the scales increasingly tip in favor of industry as regulatory frameworks tighten.
